Jörg Schüttrumpf1, M Kai Hourfar, Sonja Alesci, Wolfgang Miesbach, Erhard Seifried, Michael Schmidt. 1. Institut für Transfusionsmedizin und Immunhämatologie, Klinikum der Johann Wolfgang Goethe Universität, DRK-Blutspendedienst Baden-Württemberg - Hessen, Frankfurt/M., Germany ; Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt/M., Germany.
Abstract
BACKGROUND: Xenotropic murine leukemia virus-related virus (XMRV) is a retrovirus that has recently been related to prostate cancers and chronic fatigue syndrome. Since other human-pathogenic retroviruses, such as HIV, human T-lymphotropic virus type I (HTLV-I) and -II, are known blood-transmitted pathogens, XMRV might present another hazard associated with products derived from in vitro cultures of human or animal origin, or blood component-based therapeutics. Here, we investigated whether XMRV was transmitted to individuals with hemophilia and frequent exposure to plasma-derived or recombinant clotting factors. METHODS: We used highly sensitive real-time PCR to test plasma samples from 127 consecutive individuals with hemophilia who consulted our hemophilia center either for treatment or for a standard check-up. RESULTS: From the 127 hemophiliacs, 80 had prior contact to persons with either hepatitis B (n = 30), hepatitis C (n = 74) and/or HIV (n = 21), and 30 were currently being treated with plasma-derived and 97 with recombinant factor concentrates. None of the individuals tested positive for XMRV. CONCLUSIONS: Independent of the ongoing discussion on whether the positive XMRV testing in initial reports was a result of reagent, sample, or tissue contamination, and whether XMRV is a real threat or a testing artifact, our data suggest that XMRV might not play an important role for hemophiliacs.
BACKGROUND:Xenotropic murine leukemia virus-related virus (XMRV) is a retrovirus that has recently been related to prostate cancers and chronic fatigue syndrome. Since other human-pathogenic retroviruses, such as HIV, human T-lymphotropic virus type I (HTLV-I) and -II, are known blood-transmitted pathogens, XMRV might present another hazard associated with products derived from in vitro cultures of human or animal origin, or blood component-based therapeutics. Here, we investigated whether XMRV was transmitted to individuals with hemophilia and frequent exposure to plasma-derived or recombinant clotting factors. METHODS: We used highly sensitive real-time PCR to test plasma samples from 127 consecutive individuals with hemophilia who consulted our hemophilia center either for treatment or for a standard check-up. RESULTS: From the 127 hemophiliacs, 80 had prior contact to persons with either hepatitis B (n = 30), hepatitis C (n = 74) and/or HIV (n = 21), and 30 were currently being treated with plasma-derived and 97 with recombinant factor concentrates. None of the individuals tested positive for XMRV. CONCLUSIONS: Independent of the ongoing discussion on whether the positive XMRV testing in initial reports was a result of reagent, sample, or tissue contamination, and whether XMRV is a real threat or a testing artifact, our data suggest that XMRV might not play an important role for hemophiliacs.
Authors: Robert H Silverman; Jaydip Das Gupta; Vincent C Lombardi; Francis W Ruscetti; Max A Pfost; Kathryn S Hagen; Daniel L Peterson; Sandra K Ruscetti; Rachel K Bagni; Cari Petrow-Sadowski; Bert Gold; Michael Dean; Judy A Mikovits Journal: Science Date: 2011-10-14 Impact factor: 47.728
Authors: Graham Simmons; Simone A Glynn; Anthony L Komaroff; Judy A Mikovits; Leslie H Tobler; John Hackett; Ning Tang; William M Switzer; Walid Heneine; Indira K Hewlett; Jiangqin Zhao; Shyh-Ching Lo; Harvey J Alter; Jeffrey M Linnen; Kui Gao; John M Coffin; Mary F Kearney; Francis W Ruscetti; Max A Pfost; James Bethel; Steven Kleinman; Jerry A Holmberg; Michael P Busch Journal: Science Date: 2011-09-22 Impact factor: 47.728
Authors: Harriet C T Groom; Virginie C Boucherit; Kerry Makinson; Edward Randal; Sarah Baptista; Suzanne Hagan; John W Gow; Frank M Mattes; Judith Breuer; Jonathan R Kerr; Jonathan P Stoye; Kate N Bishop Journal: Retrovirology Date: 2010-02-15 Impact factor: 4.602
Authors: Oliver Hohn; Kristin Strohschein; Alexander U Brandt; Sandra Seeher; Sandra Klein; Reinhard Kurth; Friedemann Paul; Christian Meisel; Carmen Scheibenbogen; Norbert Bannert Journal: PLoS One Date: 2010-12-22 Impact factor: 3.240
Authors: Natalia Makarova; Chunxia Zhao; Yuanyuan Zhang; Sushma Bhosle; Suganthi Suppiah; Jeanne M Rhea; Natalia Kozyr; Rebecca S Arnold; Hinh Ly; Ross J Molinaro; Tristram G Parslow; Eric Hunter; Dennis Liotta; John Petros; Jerry L Blackwell Journal: PLoS One Date: 2011-04-06 Impact factor: 3.240
Authors: Oliver Hohn; Hans Krause; Pia Barbarotto; Lars Niederstadt; Nadine Beimforde; Joachim Denner; Kurt Miller; Reinhard Kurth; Norbert Bannert Journal: Retrovirology Date: 2009-10-16 Impact factor: 4.602